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Modifications to the core histones are thought to
contribute to ESC pluripotency by priming tissue-
specific promoters and enhancers for later
activation. However, it is unclear how these marks
are targeted in ESCs and maintained during differen-
tiation. Here, we show that the ESC factor Sox2
targets H3K4methylation tomonovalent and bivalent
domains. In ESCs, Sox2 contributes to the formation
of amonovalentmark at an enhancer in the pro/pre-B
cell-specific l5-VpreB1 locus. Binding of Foxd3
suppresses intergenic transcription of the enhancer
and surrounding sequences. In pro-B cells, enhancer
activity is dependent on the Sox and Fox binding
sites, and the enhancer is bound by Sox4, which is
required for efficient expression of l5. Our results
lead us to propose a factor relay model whereby
ESC factors establish active epigenetic marks at
tissue specific elements before being replaced by
cell type-specific factors as cells differentiate.INTRODUCTION
A defining property of pluripotent embryonic stem cells (ESCs) is
their ability to activate all of the gene expression programmes
that characterize the different somatic cell types in the embryo.
There is strong evidence that this capability is the result of
intrinsic epigenetic features of ESC chromatin. In particular, the
observation that the number of viable offspring generated by
nuclear transfer is 15–20 times more efficient using nuclei from
ESCs compared with the rates obtained with nuclei from differ-
entiated cells (Rideout et al., 2001) indicates that chromatin in
ESCs has specific properties that make it more amenable to
reprogramming.
A number of studies have directly addressed this issue and
have identified epigenetic features that could distinguish ESCs
from other cell types. There is evidence that chromatin in ESCs
is more open, with higher levels of permissive transcription
from intergenic promoters (Efroni et al., 2008). Inhibition114 Cell Stem Cell 7, 114–126, July 2, 2010 ª2010 Elsevier Inc.of the proteasome was shown to activate cryptic promoters,
suggesting that ESC chromatin is accessible to RNA pol II,
necessitating continuous removal of the polymerase by protea-
somal degradation (Szutorisz et al., 2006).
Specific histone modification marks have also been identified
at, or close to, tissue-specific genes in ESCs. Two major cate-
gories of mark have been identified to date. Bivalent domains
consist of overlapping regions that are marked by the positive
histone H3K4me2/3 and negative H3K27me3 modifications
(Azuara et al., 2006; Bernstein et al., 2006). The fact that
these marks are associated with gene activation and silencing,
respectively, has led to the suggestion that they could be
involved in repressing transcription while at the same time
poising genes for activation at later stages. The bivalent
mark would then resolve to a monovalent H3K4me2/3 or
H3K27me3 mark as genes are activated or silenced during
differentiation. The picture has been complicated by the finding
that bivalent domains are also present at some genes in differen-
tiated cells (Araki et al., 2009; Roh et al., 2006). Nevertheless,
the widespread distribution of bivalent marks in ESCs sug-
gests that they could be an important epigenetic feature of
pluripotency.
In addition to bivalent modifications, localized regions of H3K4
methylation are observed close to many tissue specific genes in
ESCs without any accompanying H3K27 methylation (Mikkelsen
et al., 2007; Szutorisz et al., 2005). We term these regions
‘‘monovalent’’ domains to distinguish them from bivalent
domains as they contain only modifications that are associated
with activation. The presence of these positive monovalent
marks suggests that sequence-specific factors are already
binding to tissue-specific genes and recruiting histonemodifying
complexes at the ESC stage (Szutorisz andDillon, 2005; Xu et al.,
2007). A possible role formonovalent domainswould be to act as
platforms that promote binding of cell-type specific factors to
tissue-specific enhancers as cells differentiate. This could
constitute an additional mechanism for poising tissue-specific
promoters in pluripotent stem cells for later activation (Szutorisz
and Dillon, 2005).
We have carried out a detailed study of this type ofmonovalent
marking at a tissue-specific enhancer in the murine l5-VpreB1
locus. The l5 and VpreB1 genes are expressed in pro- and
pre-B cells, where their protein products form part of the
surrogate light chain. We have previously identified an enhancer
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upstream from the l5 promoter, which enhances expression
from a linked promoter in pre-B cells in a transgenic mouse
assay (Minaee et al., 2005). We also showed that the enhancer
is marked by a tightly localized monovalent peak of histone
H3K4 dimethylation and H3K9 acetylation in ESCs and that
this peak is absent from differentiated nonlymphoid cells
(Szutorisz et al., 2005). In pre-B cells, the intergenic enhancer
coincides with two DNase I hypersensitive sites (HS 7 and 8),
which are present in pro- and pre-B cells but are not detected
in ESCs. These results led us to propose that the presence of
the localized monovalent mark in ESCs primes the enhancer
for subsequent activation as the cells differentiate to the
pro-/pre-B cell stages (Szutorisz et al., 2005). The discrete local-
ization of the monovalent modifications on the l5-VpreB1
enhancer is indicative of specific recruitment of histone acetyl-
transferase and methyltransferase complexes through binding
of sequence-specific factors to the enhancer region.
Here, we show that the ESC factors Sox2 and Foxd3 bind to
the l5-VpreB1 intergenic enhancer in ESCs. Binding of Sox2
contributes to the establishment of the H3K4 dimethylation
mark, whereas Foxd3 represses intergenic transcription from
the enhancer. In pro-B cells, the Sox sites in the enhancer are
bound by Sox4, and the Sox and Fox binding sites are required
for full enhancer activity. Sox2 is also involved in targeting H3K4
di- and trimethylation to a bivalent domain at the 50 end of the
Pax5 gene. Our results provide support for a factor relay model
whereby ESC factors establish epigenetic marking at tissue-
specific genes and then hand over to cell type-specific factors
as cells commit to specialized lineages.
RESULTS
The l5-VpreB1 Enhancer Is Hypersensitive
to DNase I Digestion in ESCs
The monovalent peak of histone H3K4 dimethylation, which is
present in the l5-VpreB1 locus in ESCs, coincides with a region
that becomes hypersensitive to DNase I at the pro-/pre-B cell
stage (DNase I HS8, Figure 1A) (Minaee et al., 2005). However,
conventional DNase I HS mapping does not detect a DNase I
HS at this position in ESCs, despite the presence of the histone
modifications (Szutorisz et al., 2005). A possible explanation for
the failure to detect the HS could be that chromatin in ESCs is
in a more generally open configuration, which would prevent
the HS from being visible in the context of a higher level of
DNase I digestion of the surrounding chromatin. Therefore,
we subjected the HS8 region to DNase I in vivo footprinting,
on the basis that the higher resolution of this method would
allow us to compare the sensitivity of the region to DNase I in
ESCs, pro-B cells, and differentiated nonlymphoid cells. The
results of the analysis are shown in Figures 1B and 1C.
Comparison of the footprints obtained in pro-B cells with the
patterns obtained in liver cells showed a region of increased
sensitivity to digestion in pro-B cells that coincides closely
with the position of the pre-B cell-specific HS. The region
was relatively insensitive to digestion in the nonlymphoid liver
cells, confirming previous observations that HS8 is pre-B cell
specific. However, when the region was subjected to DNase I
footprinting in ESCs, a pattern of digestion was observed thatwas very similar to the one obtained in pre-B cells (Figures
1B and 1C). These results indicate that the chromatin structure
of the intergenic enhancer in ESCs resembles the open config-
uration that it adopts in pro-B cells but differs markedly from
the more closed configuration that is present in differentiated
nonlymphoid cell types.
The l5-VpreB1 Enhancer Is Bound by Sox2 and Foxd3
in ESCs
Inspection of the sequence of the DNase I sensitive region at
HS8 revealed the presence of a consensus binding site for
members of the Sox family of transcription factors (which we
call the Sox-A site). The region also contained a consensus
site for members of the forkhead box (Fox) family. To test
whether these sites are occupied in ESCs, DMS in vivo foot-
printing was carried out on nuclei from ESCs using the primers
that cover the DNase I-sensitive region. The results show the
presence of clear footprints on both binding sites in ESCs and
pro-B cells, but not in NIH 3T3 cells (Figures 1D and 1E).
Some of the footprinted bands were similar in ESCs and pro-
B cells, but there were also differences between the two cell
types, suggesting that different factors bind to the sites at
different stages of development. Sequence inspection also re-
vealed the presence of an additional Sox site (which we call
the Sox-B site) at the 50 end of HS8 and DMS in vivo footprinting
showed that this site is also occupied in ESCs and in pro-B cells
(Figure S1 available online). The DMS footprints were not
completely identical in the two cell types, indicating that there
are differences in the protein-DNA contacts at the HS8 region
in ESCs and pro-B cells. This strongly suggests that there is
a switch in the factors that bind to the enhancer during commit-
ment to the B cell lineage.
Sox2, a member of the Sox family of transcription factors, has
been shown to play a key role in maintaining ESC pluripotency
(Avilion et al., 2003) and is also involved in neural differentiation
and development of the eye (Ferri et al., 2004; Lang, 2004).
Foxd3, a member of the forkhead transcription factor family, is
known to be involved in promoting self renewal and survival of
mouse ESCs and preventing differentiation of ESCs and neural
crest progenitors (Liu and Labosky, 2008). The expression
patterns of these two factors and the roles that they play in main-
taining ESC pluripotency made them potential candidates for
binding to the Sox and Fox sites in the HS8 region.
Chromatin immunoprecipitation (ChIP) analysis was used
to analyze the binding pattern of Sox2 and Foxd3 across the
l5-VpreB1 locus. Crosslinked sonicated chromatin from undif-
ferentiated ESCs was precipitated with anti-Sox2 or anti-
Foxd3 antibodies. Precipitated DNA was analyzed by real-time
PCR using primers specific for different points in the locus
(Figure 2A). The results are shown in Figures 2B and 2C. Clear
peaks of enrichment were observed for both Sox2 and Foxd3
using three different primer sets that amplify the HS8 region.
The enrichment for Foxd3 also extended into the region that
contains HS7. No enrichment was observed across the rest of
the l5-VpreB1 locus or on the neighboring constitutive topoiso-
merase-3b promoter. Together with the results of the in vivo
footprinting, these data clearly indicate that Sox2 and Foxd3
bind to specific sites in the l5-VpreB1 intergenic enhancer in
ESCs.Cell Stem Cell 7, 114–126, July 2, 2010 ª2010 Elsevier Inc. 115
Figure 1. DNase I Sensitivity and Factor Binding at the l5-VpreB1 Intergenic Enhancer in ESCs
(A) The murine l5-VpreB1 locus showing the location of the monovalent H3K4 dimethylation mark and the position of the DNase I hypersensitive sites (HS). HS1
and HS11 are constitutive. HS2 to -10 are restricted to pro- and pre-B cells.
(B) DNase I in vivo footprinting of a segment of the intergenic enhancer in ESCs, pro-B cells, and liver cells. G, purified genomic DNA treated with DNase I. DMS-
treated genomic DNA (G DMS) was used to provide a sequence ladder.
(C) Intensity scans of lanes 2, 4, and 6 of the gel in (B). Vertical black lines show the location of the consensus Sox and Fox binding sites. Red bars indicate regions
of hypersensitivity. Numbers indicate positions relative to the l5 transcription start site.
(D) DMS in vivo footprinting analysis of the region analyzed in (B) in ESCs, pro-B cells, and NIH 3T3 cells. G, DMS-treated genomic DNA used as sequence refer-
ence. Circles indicate the locations of protected nucleotides.
(E) Sequence of part of the analyzed region showing the positions of the consensus Sox and Fox sites and the positions of DNase I hypersensitive regions (red
lines) and DMS footprinted bases (open circles).
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Locus in ESCs
The close juxtaposition of the Sox-A site and the Fox site raises
the possibility of cooperative or antagonistic interactions
between Sox2 and Foxd3 at HS8. To test this possibility,
Sox2 was knocked down by transfecting ESCs with siRNA
that specifically targets Sox2 mRNA. Efficient reduction in the
level of Sox2 protein was confirmed by western blotting
(Figure S2A). The cells did not show significant changes in
morphology or in expression of ESC markers during this period
of transient Sox2 knockdown (Figures S2B and S2C), and no
change was observed in the levels of Foxd3 expression (data
not shown). ChIP analysis of the siRNA-treated cells with an
anti-Foxd3 antibody showed that the Sox2 knockdown resulted
in a substantial increase in Foxd3 enrichment at HS8 and HS7
(Figure 2D).
An ESC line in which the Foxd3 gene was flanked by loxP sites
was used to conditionally inactivate the Foxd3 gene by tamox-
ifen-induced activation of a cre-estrogen receptor fusion protein
(Liu and Labosky, 2008). Loss of Foxd3 expression was
confirmed by qRT-PCR analysis of mRNA isolated 48 hr after
tamoxifen treatment (Figure S3A). The cells did not show any
morphological evidence of differentiation at this point and
continued to express ESC markers (Figures S3B and S3C),
and no change was observed in the level of Sox2 expression
(data not shown). Inactivation of the Foxd3 gene did not affect
binding of Sox2 to the HS7/HS8 region (Figure 2E). These results
suggest that binding of Sox2 antagonizes Foxd3 binding to the
HS7/HS8 region, but not vice versa.
Sox2 Is Involved in Targeting Methylation of Histone
H3K4 to the l5-VpreB1 Intergenic Enhancer in ESCs
Binding of Sox2 and Foxd3 to the HS7/8 region of the l5-VpreB1
locus in ESCs suggests that these factors could be involved in
generating the localized histone modification mark by recruiting
histone methyltransferases to the region. In order to test this
possibility directly, ChIP analysis of histone H3K4 dimethylation
was carried out on the Sox2 knockdown and Foxd3 conditional
knockout ESCs. Analysis of the H3K4me2 profile following
siRNA knockdown of Sox2 showed a clear reduction in the levels
of the modification at HS8 (Figure 2F). No change was observed
in regions of the locus where Sox2 does not bind. ChIP analysis
also detected a peak of H3K4 trimethylation on the HS8 region in
ESCs, and knockdown of Sox2 reduced the level of H3K4me3 at
HS8 (Figure S4).
In contrast, analysis of ESCs that had the Foxd3 gene condi-
tionally knocked out showed no change in the profile of histone
H3K4me2 across the locus (Figure 2G). These results indicate
that Sox2 is involved in generating the localized peak of histone
modifications at the l5-VpreB1 intergenic enhancer in ESCs,
whereas Foxd3 does not seem to have any role in targeting
histone modifications to the region.
Foxd3 Represses Intergenic Transcription
in the l5-VpreB1 Locus in ESCs
Permissive transcription is widespread in ESCs and results in
high levels of aberrant transcripts that are initiated at intergenic
promoters (Efroni et al., 2008). It has been suggested that this
global transcription is a signature of ‘‘stemness,’’ which acts tokeep chromatin in an open, permissive state (Efroni et al.,
2009). Mapping of intergenic transcription in the l5-VpreB1
locus in ESCs showed that HS8 contains an intergenic promoter
(Szutorisz et al., 2005), and intergenic transcription was also
found to initiate from the HS7 region in ESCs under conditions
of proteasome inhibition (Szutorisz et al., 2006). To test whether
binding of Sox2 affects intergenic transcription, real-time RT-
PCR analysis was used to detect intergenic transcripts in the
region upstream from the l5 promoter in cells transfected with
anti-Sox2 siRNA (see Supplemental Experimental Procedures).
A slight reduction in the levels of intergenic transcripts was
observed following knockdown of Sox2, but the difference was
not statistically significant (Figure 3A).
ESCs that had the Foxd3 gene conditionally inactivated were
also analyzed for intergenic transcription in the locus. Real-
time PCR analysis showed a substantial increase in the level of
intergenic transcripts in the ESCs that lacked Foxd3
(Figure 3B). The highest levels were observed at HS7 and HS8,
but elevated levels were also observed at the VpreB1 promoter
and at the 30 end of the VpreB1 gene. Transcription across the
l5 promoter did not show a significant increase. The results of
this analysis suggest that Foxd3 has a direct role in suppressing
intergenic transcription across parts of the l5-VpreB1 locus.
To further test the role of the Sox and Fox binding sites in regu-
lating transcription in ESCs, a reporter construct that placed the
intergenic enhancer upstream of a l5 promoter driving expres-
sion of a human b-globin gene was transiently transfected into
ESCs. It was previously shown that high levels of intergenic tran-
scription are initiated from within the reporter gene, but not from
the promoter in this construct in ESCs (Szutorisz et al., 2006).
Mutation of the Sox binding site abolished transcription in this
construct, whereas mutation of the Fox site increased transcrip-
tion by approximately 2-fold (Figure 3C). This result further
supports the conclusion that Foxd3 is involved in suppressing
permissive transcription in the locus in ESCs. The much greater
effect of mutating the Sox site compared with the slight reduc-
tion in intergenic transcription of the endogenous locus observed
for the knockdown of Sox2 could be because of redundant func-
tions of other transcription factors that operate more effectively
in a chromosomal context.
Sox4 Binds to the l5-VpreB1 Intergenic Enhancer
and Increases l5 Expression at the Pro-/Pre-B Cell
Stage
The results of the in vivo footprinting show that the Sox and Fox
sites located in HS8 are also occupied in pro-B cells when the in-
tergenic enhancer is active and the l5 and VpreB1 genes are
transcribed. To test whether the Sox and Fox sites are required
for the enhancer function, the reporter construct containing the
l5 promoter and the HS7/8 region (Figure 3C) was transiently
transfected into a Rag-2-deficient Abelson transformed pro-B
cell line, which expresses l5 and VpreB1. Addition of the
enhancer resulted in a 4-fold increase in expression compared
with the level obtained for the l5 promoter alone (Figure 4A).
Mutation of both Sox sites reduced this level by 2-fold, as did
a separate mutation of the Fox consensus binding site. Mutation
of the two Sox sites and the Fox site in the same construct
reduced expression to the basal level obtainedwith the promoter
only (Figure 4A). These results indicate that as well as beingCell Stem Cell 7, 114–126, July 2, 2010 ª2010 Elsevier Inc. 117
Figure 2. Sox2 and Foxd3 Bind to the Intergenic Enhancer in ESCs
(A) The l5-VpreB1 locus showing the positions of the PCR primers used for ChIP.
(B and C) ChIP analysis of binding of Sox2 (B) and Foxd3 (C) to the l5-VpreB1 locus. Red bars show the level of enrichment obtained using nonspecific Ig.
(D) Effect of Sox2-specific siRNA on binding of Foxd3 to the locus in ESCs.
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Figure 3. Binding of Foxd3 Suppresses Intergenic Transcription in the l5-VpreB1 Locus
(A) Intergenic transcription in ESCs in which Sox2 has been subjected to siRNA-mediated knockdown.
(B) Transcription of the l5-VpreB1 intergenic region in Foxd3 conditional knockout ESCs. Levels are shown as fold expression relative to untreated cells.
(C) Effect of the Sox and Fox sites on transcription in ESCs. Constructs containing the human b-globin gene under the control of the murine l5 promoter alone
(L5P-G) or downstream of the HS7/8 enhancer (HS7/8-L5P-G) were analyzed by transient transfection of ESCs. The analysis was carried out on the wild-type
enhancer (WT) and on enhancers in which both Sox sites (Sox-m) or the Fox site (Fox-m) were mutated. Levels are expressed relative to the level obtained
with L5P-G. Mean values and standard error of the mean were calculated from three independent experiments. Asterisks indicate significant differences
(p < 0.01 in Student’s t test).
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together to generate the enhancer activity of the HS7/8 region
in pro-B cells.
Since Sox2 and Foxd3 are not expressed in pro-B cells
(Figure S5), this observation suggested that other members of
the Sox and Fox families are involved in regulating the locus at
this stage. Sox4 is a member of the Sox family that has been
shown to have important roles in the development of T and B
lymphocytes, as well as being involved in cardiogenesis and
the formation of pancreatic islet cells, osteoblasts, and neural
and glial cells (Lefebvre et al., 2007). Inactivation of the Sox4
gene in hematopoietic cells results in a block to B cell develop-
ment at the early pro-B cell stage, which seems to be because
of a defect in the capacity of pre-pro-B cells to proliferate prior
to the first Ig rearrangement events (Schilham et al., 1996).
To determine whether Sox4 binds to the intergenic enhancer
at the pro-B/pre-B cell stage, ChIP analysis was carried out on
chromatin from a pro-B cell line using antibodies that recognize(E) Effect of Foxd3 conditional knockout (KO) on binding of Sox2 to the locus.
(F and G) Effect of Sox2-specific siRNA (F) and conditional Foxd3 conditional kno
locus in ESCs. Histograms and error bars show mean values and standard error o
cate significant differences: p < 0.01 in Student’s t test (B and C) or ANOVA (D aSox4. The results show a strong peak of enrichment for Sox4 on
the region containing HS7 and HS8 (Figure 4B). A smaller enrich-
ment peak was observed on HS1 and HS2 at the 30 end of the
locus. There was no significant enrichment for Sox4 on the l5
or the VpreB1 promoters.
In order to directly test whether Sox4 is involved in regulating
l5 expression, we analyzed the effects of ectopic expression of
Sox4 in Ba/F3 early pro-B cells. Ba/F3 is a cytokine-dependent
early pro-B cell line, which does not normally express l5 and
VpreB1 but has been shown to activate the genes in response
to ectopic expression of EBF and an E47 forced dimer (Sigvards-
son et al., 1997). Transfection of EBF and E47 forced dimer
expression constructs into Ba/F3 gave the expected activation
of the endogenous l5 gene (Figure 4C). Cotransfection of
a Sox4 expression construct resulted in a significant enhance-
ment of the effect of EBF and E47 alone on l5 expression
(Figure 4C). The effect of knocking down Sox4 expression in
pre-B cells was also analyzed by transient transfection of anckout (G) on the levels of histone H3K4me2 enrichment across the l5-VpreB1
f the mean (SEM) from at least three independent experiments. Asterisks indi-
nd F).
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Figure 4. Sox4 Binds to the l5-VpreB1 Intergenic Enhancer and Increases l5 Expression in Pro- and Pre-B Cells
(A) Effect of mutating the Sox and Fox sites on the activity of the intergenic enhancer. The reporter constructs shown in Figure 3C were transfected into pro-B
cells, and levels of reporter gene transcription were measured by qRT-PCR. WT, wild-type enhancer; Sox-m, mutation of both Sox sites; Fox-m, mutation of the
Fox site; Sox/Fox-m, mutation of both Sox sites and the Fox site. Values represent levels relative to those obtained for the l5 promoter only construct (mean ±
SEM for three experiments).
(B) ChIP analysis carried out on Abelson-transformed RAG-knockout pro-B cells shows binding of Sox4 to the l5-VpreB1 locus. Positions of the primers used for
the analysis are shown in Figure 2A.
(C) Effect of transfection of Ebf1/E47 or Ebf1/E47 plus Sox4 on l5 transcription in Ba/F3 early pro-B cells (see Experimental Procedures for details). The bars show
mean l5 expression ± SEM relative to cells transfected with Ebf1/E47 only (four independent experiments). A Q-test (confidence > 99%) was used to exclude one
experiment, which gave a 15-fold increase in l5 expression and was considered to be an outlier.
(D) Effect of Sox4-specific siRNA on the expression of Sox4 and l5 in B3 pre-B cells. Values represent the percentage expression of Sox4 (red) and l5 (green)
relative to cells transfected with nonspecific (mock) siRNA (mean ± SEM from four independent experiments). Asterisks in all panels indicate significant differ-
ences (p < 0.01 in Student’s t test).
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VpreB1. Analysis of mRNA levels showed that Sox4 expression
was reduced to around 40% of the normal level and that this re-
sulted in a significant reduction in l5 expression (Figure 4D).
Since the highest levels of Sox4 binding are to the intergenic
enhancer (Figure 4B), these results provide strong evidence
that the enhancer has an important role in activating l5 expres-
sion during B cell differentiation.
The identityof the factor thatbinds to theFoxsite inpro-andpre-
B cells remains to be determined. Possible candidates are the
Forkhead factors Foxp1 and Foxo1. Both of these factors bind to
similar consensus binding sites in the Erag enhancer in the
RAG1/RAG2 locus and havebeen shown to be necessary for early
Bcelldevelopment (Dengler etal., 2008;Huetal., 2006).ChIPanal-
ysis of Foxp1 binding to the l5-VpreB1 locus showed a broad120 Cell Stem Cell 7, 114–126, July 2, 2010 ª2010 Elsevier Inc.pattern of binding across the locus (data not shown), which
suggests thatFoxp1mayhaveseveral different roles in locus regu-
lation, including a possible domain-opening function.
Sox4 Binds to the l5-VpreB1 Intergenic Enhancer
in Hemangioblasts
Our results suggest a transition from Sox2 to Sox4 binding at the
HS8 region as ESCs commit to hematopietic lineages. To further
investigate the timing of this transition, we analyzed binding of
Sox4 to the intergenic enhancer in hemangioblasts. The heman-
gioblast has been characterized as a common progenitor cell for
the hematopoietic and endothelial lineages and, therefore,
represents one of the earliest stages of commitment to the
hematopoietic lineages (Lancrin et al., 2009). ESCs expressing
a GFP gene under the control of the Brachyury promoter were
Figure 5. The l5-VpreB1 Intergenic Enhancer Is Marked by H3K4 Dimethylation and Bound by Sox4 in Hemangioblasts
ChIP analysis of H3K4 dimethylation (A) and binding of Sox4 (B) to the l5-VpreB1 locus in hemangioblasts purified from differentiated embryoid bodies (see
Experimental Procedures for details). Red bars show the level of enrichment obtained using nonspecific Ig. Positions of the primers used for the analysis are
shown in Figure 2A.
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dissociated, and hemangioblasts were purified by sorting for
GFP and Flk1 expression (Fehling et al., 2003). RT-PCR analysis
detected expression of Sox4 in the hemangioblasts (Figure S5C).
Transcripts were not detected for Sox2 or Foxd3.
ChIP analysis showed the presence of a peak of H3K4 dime-
thylation at the HS8 region in chromatin isolated from the purified
hemangioblasts (Figure 5A). Analysis of Sox4 binding revealed
a peak of enrichment for Sox4 that coincided with the
H3K4me2 enrichment peak (Figure 5B). These results indicate
that the transition from Sox2 to Sox4 binding to the intergenic
enhancer takes place at a very early stage of hematopoietic
commitment.
Sox2 Is Involved in Generating Histone Modification
Peaks at the Pax5 and Blink/Dntt Loci in ESCs
Our findings raise the possibility that Sox2 and other ESC factors
have a more general role in establishing active histone modifica-
tionmarks at tissue-specific genes. Previous genome-wide ChIP
studies have identified multiple monovalent and bivalent peaks
of H3K4 methylation in ESCs. A microarray analysis of the
Pax5, Blink/Dntt, and Ebf1 loci revealing the existence of several
such peaks is shown in Figure 6 and Figure S6. The Pax5 gene
plays an essential role in maintaining cell-type specific expres-
sion patterns throughout B cell development (Cobaleda et al.,
2007).
The microarray analysis detected a broad peak of H3K27me3
at the 50 end of the gene and a narrower peak of H3K4me2
located 2 kb upstream from the transcription start site, which
together generate a bivalent mark close to the promoter
(Figure 6). ChIP-qPCR analysis showed that this region was
also enriched for H3K4me3 (Figure 7B). The H3K4 methylation
peak coincides with a strong peak of Sox2 binding (Figure 6
and Figure S7A) and a weaker peak of enrichment for Foxd3
(Figure 6 and Figure S7B). Knockdown of Sox2 by siRNA re-sulted in a reduction in the level of H3K4me2 and H3K4me3
(Figure 7). Interestingly, the Sox2 knockdown had a particularly
strong effect on the level of H3K4me3, reducing this modification
to baseline levels. This result suggests that Sox2 plays a central
role in targeting the H3K4me3 modification to the Pax5 bivalent
domain. No effect on the levels of H3K4me2 was observed in the
conditional Foxd3 knockout cells (data not shown). In pro-B
cells, a peak of Sox4 binding is observed at the same position
(Figure 6 and Figure S7C). These data indicate that Sox2 is
involved in establishing a bivalent domain at a gene that encodes
a key regulator of B cell differentiation.
The Blink and Dntt genes code for the Slp65 pre-B cell
signaling protein and the enzyme terminal deoxytransferase,
which is expressed in B and T cells. A monovalent peak of
enrichment for H3K4me2 and H3K4me3 was observed in the
region between the two genes (Figure S6 and Figure 7), and
this coincided with a peak of Sox2 binding. In ESCs where
Sox2 was knocked down, the level of H3K4me2 at this position
was significantly reduced and the level of H3K4me3 was
reduced to baseline levels (Figures 7A and 7B). Analysis of the
Ebf1 gene, which codes for a major regulator of B cell develop-
ment, revealed several bivalent regions, including a strong
bivalent domain at the promoter (Figure S6). No enrichment for
Sox2 or Foxd3 was detected (Figure S6), and the knockdown
of Sox2 had no effect on levels of H3K4 methylation in the
Ebf1 promoter bivalent domain (Figure 7). This result supports
the conclusion that binding of Sox2 is directly involved in target-
ing H3K4methylation to a proportion of bivalent andmonovalent
regions in ESCs.
To test whether Sox2 has a role in targeting polycomb binding
and H3K27 methylation to bivalent domains, ChIP analysis of
H3K27me3 and binding of the polycomb protein Suz12 was
carried out following knockdown of Sox2. No effect was
observed on H3K27 methylation or Suz12 binding (Figures 7C
and 7D). Overall, our results demonstrate that Sox2 plays anCell Stem Cell 7, 114–126, July 2, 2010 ª2010 Elsevier Inc. 121
Figure 6. Sox2 and Foxd3 Binding Colocalize with the Pax5 Bivalent Domain
Log2 ratio profiles (IP versus Input) and enrichment peaks of H3K4me2, H3K27me3, Sox2, and Foxd3 in ESCs and Sox4 in RAG/ pro-B cells at the Pax5 locus.
Peak detection was carried out as described in Experimental Procedures. Results were validated by qPCR ChIP (Figure S7).
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ESC Factors Prime a Pre-B Cell Enhanceressential role in establishing regions of H3K4 methylation that
form part of monovalent and bivalent marks at several key
tissue-specific genes in ESCs but does not seem to be involved
in targeting H3K27 methylation to bivalent domains.
DISCUSSION
A significant body of data indicates that many tissue-specific
genes that are silent in pluripotent ESCs are kept in a poised state,
ready for expression when the cells start to differentiate and
commit to specific lineages (Spivakov and Fisher, 2007). Poly-
combproteinshavebeen implicated ingeneratingbivalenthistone
modification domains, which are thought to contribute to this type
of priming for later expression (Azuara et al., 2006;Bernstein et al.,
2006). However, PRC complexes and bivalent domains are
present in many differentiated cell types and current evidence
suggests that polycomb proteins have limited sequence speci-
ficity in mammals. This makes it unlikely that they are responsible
on their own for epigenetic priming of tissue-specific genes.
Our results highlight the role of ESC factors in priming tissue-
specific genes for expression at later stages. A number of
sequence-specific transcription factors have been described
that play essential roles in ESC pluripotency and self-renewal
(reviewed in Pan and Thomson, 2007). The data in this paper
show that two ESC factors, Sox2 and Foxd3, bind to a pro-/
pre-B cell specific intergenic enhancer in the l5-VpreB1 locus
and provide evidence that they are involved in priming the
enhancer for activation during B cell differentiation. Sox2 is
involved in the formation of the localized peak of histone H3K4
di- and trimethylation on the intergenic enhancer in ESCs and122 Cell Stem Cell 7, 114–126, July 2, 2010 ª2010 Elsevier Inc.may also contribute to the generation of an altered chromatin
structure in the region.
Sox2 can bind to DNA on its own, but interactions with part-
ners such as Oct4 in ESCs and Pax6 in the developing eye
have been shown to stabilize binding and to be required for acti-
vation of the Fgf4 and d-crystallin enhancers (Inoue et al., 2007;
Yuan et al., 1995). ChIP analysis of ESC chromatin did not detect
any binding of Oct4 to the HS7/8 region in the l5-VpreB1 locus
(data not shown). Instead, our results identify an interaction
between Foxd3 and Sox2 in ESCs, with Sox2 targeting active
histone modifications to the HS8 enhancer and Foxd3 appar-
ently repressing intergenic transcription in the locus. Previous
studies have shown that Foxd3 can act as both a transcriptional
repressor and activator (Hanna et al., 2002; Pan et al., 2006;
Steiner et al., 2006). The finding that Sox2 reduces the level of
Foxd3 binding to the HS8 region makes it tempting to speculate
that Sox2 and Foxd3 work in opposition to each other at the l5-
VpreB1 intergenic enhancer. According to this model, the two
factors would balance each other with Sox2 potentiating the
formation of an ‘‘active’’ chromatin structure at the enhancer,
whereas Foxd3 would act to prevent uncontrolled transcription
of the intergenic region and the l5 and VpreB1 genes, thereby
helping to keep the locus in a poised state.
In pro-B cells, where the genes in the l5-VpreB1 locus are
actively transcribed, the enhancer is bound by Sox4, which is
required for efficient expression of l5. Mutagenesis of the Sox
and Fox binding sites in the enhancer abolishes its activity at
the pro-B cell stage. These results suggest a factor relay model
where Sox2 binds initially to HS8 in the pluripotent cells of the
inner cell mass (ICM) of the developing blastocyst and is then
Figure 7. Sox2 Targets Histone H3K4 Methylation to Monovalent and Bivalent Domains
Effect of siRNA-mediated knockdown of Sox2 on H3K4 di- and trimethylation (A and B), H3K27 trimethylation (C), and binding of the polycomb protein Suz12 (D).
H3K27 trimethylation and binding of Suz12 were measured at the Pax5 and Ebf1 loci.
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lineage. Support for such a model comes from the observation
that Sox4 has already bound to the intergenic enhancer and re-
placed Sox2 in the hemangioblast, which is a very early progen-
itor for the hematopoietic and endothelial lineages.
The binding of Foxd3 to the enhancer in ESCs and the require-
ment of the Fox site for full enhancer activity in pro-B cells raise
the possibility of a similar factor relay between Foxd3 and other
members of the Forkhead family of factors. In this case, there
would be a switch from a repressive function for Foxd3 in
ESCs to an activating function for the factor that binds to the
Fox site in pre-B cells. The Forkhead factors Foxp1 and Foxo1
are potential candidates for the B cell component of such a relay
and other Forkhead factors could be involved at intermediate
stages. Evidence that Foxd3 can play this type of role comes
from a recent study by Xu et al. (2009), which showed thatbinding of Foxd3 generates a DNA methylation-free window at
the albumin enhancer in mouse ESCs before being replaced
by Foxa1 as the cells differentiate into endoderm.
We have also demonstrated that Sox2 binds to a region
upstream from the Pax5 promoter in ESCs and contributes to
the formation of the H3K4 methylation component of a bivalent
domain near the promoter. Pax5 has been shown to play a critical
role in maintaining cell-type-specific gene expression patterns
during B cell differentiation (Cobaleda et al., 2007). The region
upstream from the Pax5 promoter belongs to a subcategory of
bivalent domains that have broad regions of H3K27 trimethyla-
tion and more localized peaks of H3K4 methylation. Our results
demonstrate the involvement of Sox2 in the formation of the
Pax5 bivalent domain. The observation that Sox4 binds to the
same region in pro-B cells raises the possibility that factor relays
can also be initiated from within bivalent domains in ESCs.Cell Stem Cell 7, 114–126, July 2, 2010 ª2010 Elsevier Inc. 123
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tion factor families that contain multiple members with homolo-
gous DNA binding domains that bind to similar consensus
sequences. The Sox and Fox families of factors are particularly
interesting as potential components of factor relays, because of
the large number of factors in both families and because of their
involvement in specifying the phenotypes of a wide variety of
different cell types (Hannenhalli and Kaestner, 2009; Lefebvre
et al., 2007).
The existence of factor relays, extending from ESCs to fully
committed cells, has implications for the mechanisms that main-
tain specific patterns of histone modification as differentiating
cells expand and proliferate. The proposed role of histone modi-
fications as transmitters of epigenetic information during cell
division is complicated by the evidence supporting a conserva-
tive mechanism for nucleosome assembly on newly replicated
DNA strands (Kaufman and Rando, 2010; Margueron and
Reinberg, 2010). Conservative assembly results in transfer of
the complete histone octamer to newly replicated DNA and de
novo assembly of new nucleosomes without templating from
preexisting histone octamers. Such a mechanism would be
expected to dilute transmission of histone modifications from
parent strands to daughter strands since only a proportion of
nucleosomes on daughter strands would carry the modifica-
tions. This would result in a gradual loss of epigenetic information
with each cell division. Factor relays have the potential to resolve
this issue by providing a mechanism for continuous replenish-
ment of epigenetic marks through binding of transcription
factors to the newly replicated DNA strands and recruitment
of histone modifying enzymes. According to this model, tran-
scription factors and histone modifications have a mutually rein-
forcing effect, which specifies the identity of enhancers and
guarantees faithful inheritance of epigenetic information from
the ESC stage through to lineage commitment and differentiation
into fully specialized cells.
EXPERIMENTAL PROCEDURES
Cell Culture
Murine E14 ESCs and Foxd3fl/fl;Cre-ER mouse ESCs were cultured as
described by Szutorisz et al. (2005). To excise the Foxd3 gene, 4-hydroxyta-
moxifen (Sigma) was added daily to the culture to a final concentration of
2 mM. RAG2-deficient Abelson transformed pro-B cells (Alt et al., 1992) were
cultured at 37C-5% CO2 in DMEM supplemented with 15% FCS, 2 mM L-
glutamine, and 50 mM b-mercaptoethanol. B3 pre-B cells (Brown et al.,
1997) were cultured at 37C 10% CO2 in Iscove’s Modified Dulbecco’s
Medium (IMDM) supplemented with 10% fetal calf serum (FCS), 2 mM L-gluta-
mine, 50mM b-mercaptoethanol, and 2 ng/ml IL-7. BaF3 cells were cultured at
37C 10% CO2 in RPMI 1640 supplemented with 15% fetal calf serum (FCS),
2 mM L-glutamine, 50 mM b-mercaptoethanol, and 1 ng/ml IL-3.
Isolation of Hemangioblasts
Undifferentiated Bry201 ESCs were a kind gift from Dr. Valerie Kouskoff
and were maintained and differentiated as described by Fehling et al. (2003).
For embryoid body differentiation, cells were grown for one passage without
PEFs in predifferentiation medium (IMDM supplemented with 15% FCS,
monothyoglicerol [104 M], l-glutamine [2 mM], penicillin, and streptomycin),
and then resuspended in differentiation medium (IMDM supplemented
with 15% FCS, monothyoglicerol [4 3 104 M], transferrin 300 mg/l [Roche
10652202001], ascorbic acid [Sigma cat n A4544], l-glutamine, penicillin,
streptomycin) at a concentration of 25,000 cells/ml and plated in nonadherent
Petri dishes. At 3.75 days of differentiation, EBs were harvested and dissoci-124 Cell Stem Cell 7, 114–126, July 2, 2010 ª2010 Elsevier Inc.atedby trypsinisation andpassage through a 16Gneedle and stained for FACS
analysis (200 at room temperature). Cells were stained with anti-Flk1 antibody
(BD Bioscience), and GFP+Flk1+ cells were isolated by FACS sorting.Plasmids
Generation of the HS7/8-L5P-b-globin reporter has been previously reported
(Szutorisz et al., 2006). Mutagenesis of the Sox and Fox sites was performed
using the QuikChange II XL Site-Directed Mutagenesis kit (Stratagene).Cell Transfection
ESCs were transfected with 25 pmol of Sox2-specific or mock siRNA (Ambion)
per 105 cells using Lipofectamine 2000 (Invitrogen) as previously described
(Szutorisz et al., 2006). Parallel experiments using 25 pmol/105 cells of
BLOCK-iT fluorescein-labeled dsRNA (Invitrogen) showed that transfection
efficiencies were greater than 90%. Transfection of plasmids was performed
using 4 mg of DNA. Transfection efficiency was assessed by cotransfection
of a GFP expression plasmid (1 mg for ESCs, 0.2 mg for Ba/F3 cells). Transfec-
tion of pro- and pre-B cells and Ba/F3 cells was performed using a Nucleofec-
tor (Amaxa) and a LonzaCell Line Nucleofector Kit V (RAGPro-B cells andBa/
F3 cells) or Kit II (B3 cells). B3 cells were transfected with 2 uM of pooled Sox4-
specific or control silencer siRNA (Ambion) per 3 3 106 cells. Cotransfection
with 2 uM of siGLO (Dharmacon) was used to assess transfection efficiency.
Cells were harvested at 24 hr.In Vivo Footprinting
DNase I and DMS in vivo footprinting were carried out as described by (Tagoh
et al., 2006) withminormodifications. Full details can be found in Supplemental
Information.ChIP and Microarray Analysis
Chromatin immunoprecipitation experiments were performed on formalde-
hyde fixed cells as described by Szutorisz et al. (2005) using the following anti-
bodies: anti-H3K4me2 (Abcam), anti-H3K27me3 (Millipore), anti-Sox2 (Santa
Cruz Biotechnology), anti-Sox4, anti-Foxd3 (Millipore). Primer sequences are
available on request. Values for enrichment of precipitated DNA over input
were calculated as described by Litt et al. (2001). For hybridization to microar-
rays, the precipitated DNA was amplified using the GenomPlex-Whole
Genome Amplification system (Sigma-Aldrich). The amplified input and pull-
down DNA were labeled with Cy3 and Cy5 by random priming and hybridized
to the microarray by NimbleGen Systems. The microarray was comprised of
50-mer oligonucleotides probes, with a 100 bp resolution. High-frequency
repeats were excluded from the array, and each probe was represented in
duplicate. Input and pull-down signal intensities, and scaled log2 ratios were
provided by NimbleGen. Duplicated probes were separated and considered
as technical replicates. Peak detection was carried out by applying the
HMM algorithm of TileMap (Ji and Wong, 2005), and probes with a posterior
probability greater than 0.6 were considered to be significantly bound.Gene Expression Analysis by RT-qPCR
Total RNA isolated using the SV Total RNA Isolation kit (Promega). RNA (200
ng) was reverse-transcribed into cDNA using 20U SuperScript II reverse tran-
scriptase (Invitrogen) and 100 ng random primers in 20 ml final volume. Real-
time PCR analysis of 2 ml cDNA was performed using the DNA Engine Opticon
System (Biorad) and SYBRGreen Master Mix (Sigma-Aldrich). Primer
sequences are described in Szutorisz et al. (2006). Expression was normalized
against that of the ubiquitously expressed MLN51 gene to correct for differ-
ences in reverse transcription efficiency. Variation in transfection efficiency
was corrected by measuring GFP expression.SUPPLEMENTAL INFORMATION
Supplemental information includes seven figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/
j.stem.2010.05.020.
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